|
|
||||||||

,¶
,
* Arthritis Centre of Excellence, Toronto Western Research Institute, Toronto, Ontario, Canada;
Department of Immunology and
Department of Laboratory Medicine and Pathology, University of Toronto, Toronto, Ontario, Canada;
Department of Medicine, University Health Network, Toronto, Ontario, Canada; and
¶ Department of Pathology, Mount Sinai Hospital, Toronto, Ontario, Canada
Previous mapping studies have linked New Zealand Black (NZB) chromosome 4 to several lupus traits, including autoantibody production, splenomegaly, and glomerulonephritis. To confirm the presence of these traits, our laboratory introgressed homozygous NZB chromosome 4 intervals extending from either 114 to 149 Mb or 32 to 149 Mb onto the lupus-resistant C57BL/6 background (denoted B6.NZBc4S and B6.NZBc4L, respectively). Characterization of aged cohorts revealed that B6.NZBc4L mice exhibited a striking increase in splenic B1a and NKT cells in the absence of high titer autoantibody production and significant renal disease. Tissue-specific expansion of these subsets was also seen in the peritoneum and liver for B1a cells and in the bone marrow for NKT cells. Staining with CD1d tetramers loaded with an
-galactosylceramide analog (PBS57) demonstrated that the expanded NKT cell population was mainly CD1d-dependent NKT cells. The lack of both cellular phenotypes in B6.NZBc4S mice demonstrates that the genetic polymorphism(s) that result in these phenotypes are on the proximal region of NZB chromosome 4. This study confirms the presence of a locus that promotes the expansion of B1a cells and newly identifies a region that promotes CD1d-restricted NKT cell expansion on NZB chromosome 4. Taken together, the data indicate that neither an expansion of B1a cells and/nor NKT cells is sufficient to promote autoantibody production and ultimately, renal disease.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This work was supported by grants from the Canadian Institutes of Health Research and The Arthritis Society of Canada. J.E.W. is the recipient of The Arthritis Society/Canadian Institutes of Health Research Investigator Award.
2 Address correspondence and reprint requests to Dr. Joan E. Wither, Toronto Western Hospital, 1E-429C, 399 Bathurst Street, Toronto, Ontario M5T 2S8, Canada. E-mail address: jwither{at}uhnres.utoronto.ca
3 Abbreviations used in this paper: SLE, systemic lupus erythematosus; GN, glomerulonephritis; ANA, anti-nuclear Ab; int, intermediate; PI, propidium iodide; TNP, trinitrophenyl; HEL, hen egg-white lysozyme; PAS, periodic acid-Schiff; perC, peritoneal cavity; DN, double negative; DP, double positive; SP, single positive;
-galcer,
-galactosylceramide.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |